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Editorial

L-Carnitine

for Anemia in Hemodialysis Patients:
A Last Resort

Jerry Yee

Clin J Am Soc Nephrol 7: 1746–1748, 2012. doi: 10.2215/CJN.09920912

In this issue of the Clinical Journal of the American Society
of Nephrology, Mercadal and colleagues address whether
the biologically active form of carnitine, L-carnitine (LC),
offers an adjuvant erythropoietic effect to patients with
newly diagnosed ESRD undergoing maintenance hemodialysis (1). Their hypothesis, addressed in the CARNIDIAL trial (NCT 00322322) stems from abundant clinical
and bioscientiﬁc data that have suggested a multiplicity
of salutary effects of LC in the anemia of CKD.
LC is a dialyzable, 162-D quaternary amine that is not
bound to albumin in plasma and is stored primarily in
muscle. It is also known as vitamin BT (T for the Tenebrio
species) after its discovery as a mealworm growth factor in 1952 (2). It is the product of the multistep metabolism of 6-N-trimethyllysine. Carnitine production
may also be driven by the ingestion of certain foodstuffs after its methylated precursor is liberated from
proteins during normal digestion, in particular, milk
and red meat (hence its name). Nutritional supplements of carnitine abound. The biosynthesis of LC in
humans takes place principally in the kidney and
liver, a vitamin C–dependent process.
After cellular entry, LC transports cytosolic fatty
acids into the mitochondrion for b oxidation to acetyl
coenzyme (CoA) and is thus a regulator of ketogenesis.
The parent molecule is ﬁrst acylated to acylcarnitine
with acyl CoA by carnitine acyltransferase I, which is
localized to the outer mitochondrial membrane. Subsequently, the acylated moiety is translocated into the
mitochondrial matrix by a speciﬁc translocase, resident
on the outer mitochondrial membrane. Finally, acylcarnitine, via the inner mitochondrial membrane carnitine acyltransferase II, returns as carnitine to the
cytosol as acyl CoA becomes engaged in b oxidation
to acetyl CoA and, from there, to liberation of energy
through the tricarboxylic acid cycle. Aside from its
energy-productive role, especially in kidney, liver,
brain, and skeletal muscle, LC has potentially beneﬁcial roles in the maintenance of bone mass and mitigation of oxidant stress. Acting as an antioxidant, LC may
reduce lipid peroxidation, thereby reducing potential
cellular membrane damage during oxidant stress (3,4).
Plasma levels of LC are less than one tenth tissue levels,
and active transport of LC into tissues takes place. The
turnover time in kidney is approximately 24 minutes.
Plasma LC levels—both free and total—among patients
who have not yet reached ESRD may be elevated (4–6).
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However, there is a depression of the free-to-total LC
level in patients undergoing hemodialysis, and levels
may decrease 75% during a hemodialysis session because both moieties are dialyzable (7). With time, free
and total plasma levels decline in patients receiving
maintenance hemodialysis, thereby reducing plasma
free-to-total carnitine (free and acylated forms) and free
carnitine-to-acylcarnitine ratios (8). Correspondingly,
skeletal muscle–free LC in hemodialysis patients may
decrease (9,10). Because gut absorption of carnitine is
unimpaired (11), reversal of this deﬁciency by oral supplementation is biologically plausible and reasonable.
Many mechanisms have been attributed as causative
with regard to the beneﬁcial effects of LC in the anemia
of CKD. In CKD, erythrocyte, cellular free levels are
elevated, and the total carnitine level is normal, increasing the free-to-total carnitine ratio (12). However,
were LC deﬁciency to occur, several mechanisms
might contribute to the anemia of CKD. Reduced membrane stability and enhanced osmotic fragility, with a
consequent reduction of red cell half-life and suboptimal reticulocytosis, could conspire to reduce hematocrit even beyond the reduction due to erythropoietin
deﬁciency (13). Before the erythropoietin-stimulating
agent (ESA) era, Albertazzi (14) and Trovato (15) and
their colleagues observed that LC supplementation (1
g/d) increased hematocrit and reticulocyte counts in
their respective studies of 12 hemodialysis patients observed for 6 months and a separate, small, 12-month,
double-blind, placebo-controlled trial. In Trovato and
colleagues’ study (15), all 46 participants were adequately treated with folic acid, vitamin B12, and ferric
gluconate at the terminus of each hemodialysis session. LC supplementation was administered per protocol, and the 24% mean hematocrit at baseline
decreased 2%; in the treatment group, hematocrit increased 12% without the beneﬁt of ESA treatment.
Later, in ESA-treated patients, Kooistra and colleagues
observed that the total LC and free levels demonstrated an inverse relationship with hematocrit in maintenance hemodialysis patients (16). In their study, LC
demonstrated a beneﬁcial effect in patients with hematocrit ,30%. However, contradictory studies challenging the utility of LC in treating anemia in hemodialysis
patients emerged (17,18). Caruso and colleagues
established no overall effect of LC on hemoglobin levels
after 6 months of treatment in their trial (18). LC-treated
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elderly patients required a lower recombinant human erythropoietin (rHuEPO) dose to maintain their hematocrit levels
up to 3 months after trial termination compared with patients
in the control group of similar age.
Moreover, salutary effects of LC on in vitro measurements
of osmotic resistance and mechanical stability have been
documented by Matsumura and Arduini and their colleagues (19,20). Finally, LC enhances rat erythrocyte membrane
Na/K adenosine triphosphatase activity. This potentially
offsets the blunted activity of this electrogenic pump by the
uremic milieu, which may foster reduced cell survival. In
maintenance hemodialysis patients, LC, by enhancing mitochondrial delivery of free fatty acids to red cells, would reverse the slowing of the pump by these accumulating
substrates and promote membrane integrity (21,22).
In CARNIDIAL, the rHuEPO resistance index (EPO-RI)— a
ratio that expresses treatment effectiveness in units of rHuEPO
normalized to body weight to hemoglobin concentration—
was ascertained in a 1-year trial involving 92 incident hemodialysis patients. The investigation, the ﬁrst of its kind, was
conducted in a multicenter, randomized, double-blind, placebo-controlled fashion. Of the 46 patients randomly assigned to the placebo group, there were 38 completers
(83%). In the carnitine group, LC was administered prophylactically to patients with a dialysis vintage of just 40 days;
there were 35 completers (76%). Of note, placebo recipients
experienced just an 11% reduction in LC levels by month 12
of the study, less than the anticipated 20%–30% decline
(5,12). The levels of LC declined modestly in the untreated
group, and LC levels were nearly ﬁve times those of the untreated group by 3 months. Nutritional equivalence, with
plasma albumin concentration used as the benchmark, was
otherwise achieved throughout the study. The investigators
did not perform tertile or quartile trend analysis of the EPO-RI.
The demographically similar carnitine group received 1 g
of intravenous LC or approximately 14.5 mg/kg, a dose that
had been previously established to maintain LC levels within the normal range (23). At baseline, this group had mildly
lower plasma levels of albumin and hemoglobin but a greater
C-reactive protein concentration and rHuEPO dose. However, after adjustment for these variables, the EPO-RI was
considered similar in both study groups. By study end, the
temporal course of the power-transformed EPO-RI in both
groups was identical, with a mean decline of 20%–25%, indicating that ESA responsiveness improved over time in both
groups. Overall, the EPO-RI was not inﬂuenced by LC supplementation, even though the mean LC concentrations of
the treatment group were ﬁve times higher than those in the
placebo group. Achieving an EPO-RI .300 IU/kg per g hemoglobin was considered a hyporesponse. Six patients in the
untreated group versus eight in the treatment group were
hyporesponsive. In addition, no signiﬁcant differences in
plasma levels of LDL cholesterol or triglycerides between
the two groups were discerned. This issue, with the underlying tenet that LC would favorably alter the dyslipidemic
proﬁle of patients with ESRD, had been previously studied
(8). In addition, the frequency of intradialytic hypotension
episodes did not differ between groups.
The lack of efﬁcacy of LC in this study may relate to the
“insufﬁciently low” levels of LC in the participants. Specifically, and ironically, the carnitine deﬁciency in the placebo
group was insufﬁcient to allow a determination of a positive
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effect of replacement therapy. This hypothesis would also
explain why some trials have demonstrated a signiﬁcant
erythropoietic response to LC and why many clinicians, in
their respective “n of 1” trials, have witnessed a salutary response when using LC as a last-ditch effort in their hyporesponsive patients who may have endured severe carnitine
deﬁciency. In CARNIDIAL, the EPO-RI of the patients
with the lowest free carnitine levels is not reported. Perhaps
these patients actually responded positively to LC.
Finally, the water-soluble and dialyzable vitamin C/
ascorbate is itself an antioxidant and a necessary component in the biosynthesis of LC. Ascorbate has been used
concomitantly with LC in anemia trials. Perhaps some of the
success regarding anemia treatment attributed to LC has
actually derived from vitamin C administration. Congruent
with this thesis is the report of Attallah and colleagues, who
augmented an erythropoietic response in anemic hemodialysis patients with adjuvant vitamin C but without LC (24).
On balance, however, despite its putative effects, LC
supplementation should not be considered part of the
routine treatment of anemia in hemodialysis patients.
Staples such as iron, rHuEPO and its related compounds
in appropriate measure, dialytic adequacy, and all applicable
measures to reduce inﬂammation continue to represent the
safest and standardized therapeutic approach for the anemia
of CKD. LC should be used to treat anemia only in dialysis
patients with documented LC deﬁciency in whom all other
conventional measures to raise hemoglobin have been
attempted and failed.
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